BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

434 related articles for article (PubMed ID: 35849397)

  • 1. Patient and Clinician Decision Support to Increase Genetic Counseling for Hereditary Breast and Ovarian Cancer Syndrome in Primary Care: A Cluster Randomized Clinical Trial.
    Kukafka R; Pan S; Silverman T; Zhang T; Chung WK; Terry MB; Fleck E; Younge RG; Trivedi MS; McGuinness JE; He T; Dimond J; Crew KD
    JAMA Netw Open; 2022 Jul; 5(7):e2222092. PubMed ID: 35849397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of a computer-based decision aid on knowledge, perceptions, and intentions about genetic testing for breast cancer susceptibility: a randomized controlled trial.
    Green MJ; Peterson SK; Baker MW; Harper GR; Friedman LC; Rubinstein WS; Mauger DT
    JAMA; 2004 Jul; 292(4):442-52. PubMed ID: 15280342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Study protocol: a cluster randomized controlled trial of web-based decision support tools for increasing BRCA1/2 genetic counseling referral in primary care.
    Silverman TB; Vanegas A; Marte A; Mata J; Sin M; Ramirez JCR; Tsai WY; Crew KD; Kukafka R
    BMC Health Serv Res; 2018 Aug; 18(1):633. PubMed ID: 30103738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increasing referral of at-risk women for genetic counseling and BRCA testing using a screening tool in a community breast imaging center.
    Arun BK; Peterson SK; Sweeney LE; Bluebond RD; Tidwell RSS; Makhnoon S; Kushwaha AC
    Cancer; 2022 Jan; 128(1):94-102. PubMed ID: 34424535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Promoting guideline-based cancer genetic risk assessment for hereditary breast and ovarian cancer in ethnically and geographically diverse cancer survivors: Rationale and design of a 3-arm randomized controlled trial.
    Kinney AY; Howell R; Ruckman R; McDougall JA; Boyce TW; Vicuña B; Lee JH; Guest DD; Rycroft R; Valverde PA; Gallegos KM; Meisner A; Wiggins CL; Stroup A; Paddock LE; Walters ST
    Contemp Clin Trials; 2018 Oct; 73():123-135. PubMed ID: 30236776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of a Standardized Tool to Identify Women at Risk for Hereditary Breast and Ovarian.
    Hessock M; Brewer T; Hutson S; Anderson J
    Nurs Womens Health; 2021 Jun; 25(3):187-197. PubMed ID: 33933425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interdisciplinary risk counseling for hereditary breast and ovarian cancer: real-world data from a specialized center.
    Zang B; Helms M; Besch L; Kalmbach N; Stegen S; Blohmer JU; Speiser D
    Arch Gynecol Obstet; 2023 May; 307(5):1585-1592. PubMed ID: 36307613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Behavioral and psychosocial effects of rapid genetic counseling and testing in newly diagnosed breast cancer patients: design of a multicenter randomized clinical trial.
    Wevers MR; Ausems MG; Verhoef S; Bleiker EM; Hahn DE; Hogervorst FB; van der Luijt RB; Valdimarsdottir HB; van Hillegersberg R; Rutgers EJ; Aaronson NK
    BMC Cancer; 2011 Jan; 11():6. PubMed ID: 21219598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identifying Mediators of Intervention Effects Within a Randomized Controlled Trial to Motivate Cancer Genetic Risk Assessment Among Breast and Ovarian Cancer Survivors.
    An J; Lu SE; McDougall J; Walters ST; Lin Y; Heidt E; Stroup A; Paddock L; Grumet S; Toppmeyer D; Kinney AY
    Ann Behav Med; 2023 Oct; 57(11):965-977. PubMed ID: 37658805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pilot study of a culturally sensitive intervention to promote genetic counseling for breast cancer risk.
    Henderson V; Madrigal JM; Kendall LC; Parekh P; Newsome J; Chukwudozie IB; Comer-Hagans L; Coffey V; Grumbach G; Spencer S; Rodgers C; Kaur R; Balay L; Maga T; Ramamonjiarivelo Z; Balthazar C; Winn R; Watson K; Odoms-Young A; Hoskins KF
    BMC Health Serv Res; 2022 Jun; 22(1):826. PubMed ID: 35752812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.
    ; Owens DK; Davidson KW; Krist AH; Barry MJ; Cabana M; Caughey AB; Doubeni CA; Epling JW; Kubik M; Landefeld CS; Mangione CM; Pbert L; Silverstein M; Simon MA; Tseng CW; Wong JB
    JAMA; 2019 Aug; 322(7):652-665. PubMed ID: 31429903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Racial differences in the use of BRCA1/2 testing among women with a family history of breast or ovarian cancer.
    Armstrong K; Micco E; Carney A; Stopfer J; Putt M
    JAMA; 2005 Apr; 293(14):1729-36. PubMed ID: 15827311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
    Nelson HD; Pappas M; Cantor A; Haney E; Holmes R
    JAMA; 2019 Aug; 322(7):666-685. PubMed ID: 31429902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of evidence-based decision aids for women with pathogenic BRCA1 or BRCA2 variants in the german health care context: results from a randomized controlled trial.
    Kautz-Freimuth S; Redaèlli M; Shukri A; Kentenich H; Simic D; Mildenberger V; Schmutzler R; Rhiem K; Stock S
    BMC Med Inform Decis Mak; 2023 Oct; 23(1):223. PubMed ID: 37845719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of two evidence-based decision aids for female BRCA1/2 mutation carriers in Germany: study protocol for a randomised controlled parallel-group trial.
    Kautz-Freimuth S; Redaèlli M; Isselhard A; Shukri A; Vodermaier A; Rhiem K; Schmutzler R; Stock S
    Trials; 2022 Feb; 23(1):157. PubMed ID: 35172875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Young Women's Perspectives on Being Screened for Hereditary Breast and Ovarian Cancer Risk During Routine Primary Care.
    Head M; Cohn B; Wernli KJ; Palazzo L; Ehrlich K; Matson A; Knerr S
    Womens Health Issues; 2024; 34(3):268-275. PubMed ID: 38448251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Controlled trial of pretest education approaches to enhance informed decision-making for BRCA1 gene testing.
    Lerman C; Biesecker B; Benkendorf JL; Kerner J; Gomez-Caminero A; Hughes C; Reed MM
    J Natl Cancer Inst; 1997 Jan; 89(2):148-57. PubMed ID: 8998184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utilization and Outcomes of BRCA Genetic Testing and Counseling in a National Commercially Insured Population: The ABOUT Study.
    Armstrong J; Toscano M; Kotchko N; Friedman S; Schwartz MD; Virgo KS; Lynch K; Andrews JE; Aguado Loi CX; Bauer JE; Casares C; Bourquardez Clark E; Kondoff MR; Molina AD; Abdollahian M; Walker G; Sutphen R
    JAMA Oncol; 2015 Dec; 1(9):1251-60. PubMed ID: 26426480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Remotely Delivered Cancer Genetic Testing in the Making Genetic Testing Accessible (MAGENTA) Trial: A Randomized Clinical Trial.
    Swisher EM; Rayes N; Bowen D; Peterson CB; Norquist BM; Coffin T; Gavin K; Polinsky D; Crase J; Bakkum-Gamez JN; Blank SV; Munsell MF; Nebgen D; Fleming GF; Olopade OI; Law S; Zhou A; Levine DA; D'Andrea A; Lu KH
    JAMA Oncol; 2023 Nov; 9(11):1547-1555. PubMed ID: 37707822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lung Cancer Screening Decision Aid Designed for a Primary Care Setting: A Randomized Clinical Trial.
    Schapira MM; Hubbard RA; Whittle J; Vachani A; Kaminstein D; Chhatre S; Rodriguez KL; Bastian LA; Kravetz JD; Asan O; Prigge JM; Meline J; Schrand S; Ibarra JV; Dye DA; Rieder JB; Frempong JO; Fraenkel L
    JAMA Netw Open; 2023 Aug; 6(8):e2330452. PubMed ID: 37647070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.